Furthermore, versican expression increases with the acquisition of docetaxel resistance in PC-3 cells, a chemotherapeutic agent used for prostate cancer, suggesting a role of this ECM protein in resistance to treatments [79]. This evidence concerns the gene VCAN and prostate carcinoma.